PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337611
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1337611
Biologics Safety Testing Market Size and Share Analysis by Offering, Application, Test Type, End User - Global Industry Demand Forecast to 2030
The global biologics safety testing market was valued at USD 3,589.5 million in 2022, which is expected to reach USD 9,370.3 million by 2030, growing at a CAGR of 12.7% during 2022-2030.
In healthcare, biologics like cell therapies, vaccines, and monoclonal antibodies are becoming increasingly crucial. Comprehensive safety testing is required to assure the quality, efficacy, and safety of biologics as they are a new area of therapeutics that could be toxic for certain patients.
Globally, the biopharmaceutical sector is expanding significantly. The market for biologics safety testing is growing as a result of pharmaceutical companies developing and selling novel biologics.
Biologics safety testing has become more effective and accurate due to the developments in analytical methods including high-throughput screening, PCR, and next-generation sequencing. The market is driven by these technical developments because they allow for quicker and more-thorough safety checks.
The practice of customizing medical care for each patient based on their genetic composition, known as personalized medicine, is gaining popularity. The industry advance is further stimulated by the fact that biological safety testing is essential for guaranteeing the safety and effectiveness of personalized treatments.
North America dominates the biologics safety testing market. The healthcare system in North America is well-established and sophisticated, with advanced research facilities, specialized labs, and an encouraging regulatory framework. The region has become a center for biopharmaceutical research and innovation due to its infrastructure, which facilitates the creation and testing of biologics.
Most of the leading biopharmaceutical firms that create biologics operate in North America. To make sure that their products are high quality and secure, these businesses make significant investments in research and development, including safety testing.
In the field of healthcare, North America places a lot of focus on research and innovation. The presence of prestigious universities and research facilities and partnerships between academic institutions and businesses in the region enhance the use of biologics and safety testing procedures.
Consumables are essential to biologics safety testing because they provide the tools required for gathering, processing, and analyzing sample data. Reagents, test kits, culture media, pipettes, and other laboratory equipment fall under this category. Due to their importance in carrying out regular safety testing, consumables continue to be in high demand.
The market for consumables is quite competitive, with a wide variety of items being offered by multiple vendors and manufacturers. This competition encourages innovation, which results in the creation of better consumables that increase the effectiveness and precision of safety testing. The market is driven by the improvements in analytical techniques, the expansion of the biopharmaceutical sector, and the rising demand for biologics.
In the coming years, APAC will grow the fastest in the market, with an over 15% CAGR, on account of its increasing disease-ridden population. Moreover, the advancing healthcare system of regional countries is opening up doors for the providers of biologics, which, in turn, is driving the demand for their safety testing. Additionally, APAC is becoming a preferred destination for CDMO activities, including the safety testing of biologics.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by offering
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by test type
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
- 6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
- 6.2. Impact of COVID-19
- 6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes
Chapter 7. Global Market
- 7.1. Overview
- 7.2. Market Revenue, by Offering (2017-2030)
- 7.3. Market Revenue, by Application (2017-2030)
- 7.4. Market Revenue, by Test Type (2017-2030)
- 7.5. Market Revenue, by End User (2017-2030)
- 7.6. Market Revenue, by Region (2017-2030)
Chapter 8. North America Market
- 8.1. Overview
- 8.2. Market Revenue, by Offering (2017-2030)
- 8.3. Market Revenue, by Application (2017-2030)
- 8.4. Market Revenue, by Test Type (2017-2030)
- 8.5. Market Revenue, by End User (2017-2030)
- 8.6. Market Revenue, by Country (2017-2030)
Chapter 9. Europe Market
- 9.1. Overview
- 9.2. Market Revenue, by Offering (2017-2030)
- 9.3. Market Revenue, by Application (2017-2030)
- 9.4. Market Revenue, by Test Type (2017-2030)
- 9.5. Market Revenue, by End User (2017-2030)
- 9.6. Market Revenue, by Country (2017-2030)
Chapter 10. APAC Market
- 10.1. Overview
- 10.2. Market Revenue, by Offering (2017-2030)
- 10.3. Market Revenue, by Application (2017-2030)
- 10.4. Market Revenue, by Test Type (2017-2030)
- 10.5. Market Revenue, by End User (2017-2030)
- 10.6. Market Revenue, by Country (2017-2030)
Chapter 11. LATAM Market
- 11.1. Overview
- 11.2. Market Revenue, by Offering (2017-2030)
- 11.3. Market Revenue, by Application (2017-2030)
- 11.4. Market Revenue, by Test Type (2017-2030)
- 11.5. Market Revenue, by End User (2017-2030)
- 11.6. Market Revenue, by Country (2017-2030)
Chapter 12. MEA Market
- 12.1. Overview
- 12.2. Market Revenue, by Offering (2017-2030)
- 12.3. Market Revenue, by Application (2017-2030)
- 12.4. Market Revenue, by Test Type (2017-2030)
- 12.5. Market Revenue, by End User (2017-2030)
- 12.6. Market Volume, by Country (2017-2030)
- 12.7. Market Revenue, by Country (2017-2030)
Chapter 13. U.S. Market
- 13.1. Overview
- 13.2. Market Revenue, by Offering (2017-2030)
- 13.3. Market Revenue, by Application (2017-2030)
- 13.4. Market Revenue, by Test Type (2017-2030)
- 13.5. Market Revenue, by End User (2017-2030)
Chapter 14. Canada Market
- 14.1. Overview
- 14.2. Market Revenue, by Offering (2017-2030)
- 14.3. Market Revenue, by Application (2017-2030)
- 14.4. Market Revenue, by Test Type (2017-2030)
- 14.5. Market Revenue, by End User (2017-2030)
Chapter 15. Germany Market
- 15.1. Overview
- 15.2. Market Revenue, by Offering (2017-2030)
- 15.3. Market Revenue, by Application (2017-2030)
- 15.4. Market Revenue, by Test Type (2017-2030)
- 15.5. Market Revenue, by End User (2017-2030)
Chapter 16. France Market
- 16.1. Overview
- 16.2. Market Revenue, by Offering (2017-2030)
- 16.3. Market Revenue, by Application (2017-2030)
- 16.4. Market Revenue, by Test Type (2017-2030)
- 16.5. Market Revenue, by End User (2017-2030)
Chapter 17. U.K. Market
- 17.1. Overview
- 17.2. Market Revenue, by Offering (2017-2030)
- 17.3. Market Revenue, by Application (2017-2030)
- 17.4. Market Revenue, by Test Type (2017-2030)
- 17.5. Market Revenue, by End User (2017-2030)
Chapter 18. Italy Market
- 18.1. Overview
- 18.2. Market Revenue, by Offering (2017-2030)
- 18.3. Market Revenue, by Application (2017-2030)
- 18.4. Market Revenue, by Test Type (2017-2030)
- 18.5. Market Revenue, by End User (2017-2030)
Chapter 19. Spain Market
- 19.1. Overview
- 19.2. Market Revenue, by Offering (2017-2030)
- 19.3. Market Revenue, by Application (2017-2030)
- 19.4. Market Revenue, by Test Type (2017-2030)
- 19.5. Market Revenue, by End User (2017-2030)
Chapter 20. Japan Market
- 20.1. Overview
- 20.2. Market Revenue, by Offering (2017-2030)
- 20.3. Market Revenue, by Application (2017-2030)
- 20.4. Market Revenue, by Test Type (2017-2030)
- 20.5. Market Revenue, by End User (2017-2030)
Chapter 21. China Market
- 21.1. Overview
- 21.2. Market Revenue, by Offering (2017-2030)
- 21.3. Market Revenue, by Application (2017-2030)
- 21.4. Market Revenue, by Test Type (2017-2030)
- 21.5. Market Revenue, by End User (2017-2030)
Chapter 22. India Market
- 22.1. Overview
- 22.2. Market Revenue, by Offering (2017-2030)
- 22.3. Market Revenue, by Application (2017-2030)
- 22.4. Market Revenue, by Test Type (2017-2030)
- 22.5. Market Revenue, by End User (2017-2030)
Chapter 23. Australia Market
- 23.1. Overview
- 23.2. Market Revenue, by Offering (2017-2030)
- 23.3. Market Revenue, by Application (2017-2030)
- 23.4. Market Revenue, by Test Type (2017-2030)
- 23.5. Market Revenue, by End User (2017-2030)
Chapter 24. South Korea Market
- 24.1. Overview
- 24.2. Market Revenue, by Offering (2017-2030)
- 24.3. Market Revenue, by Application (2017-2030)
- 24.4. Market Revenue, by Test Type (2017-2030)
- 24.5. Market Revenue, by End User (2017-2030)
Chapter 25. Brazil Market
- 25.1. Overview
- 25.2. Market Revenue, by Offering (2017-2030)
- 25.3. Market Revenue, by Application (2017-2030)
- 25.4. Market Revenue, by Test Type (2017-2030)
- 25.5. Market Revenue, by End User (2017-2030)
Chapter 26. Mexico Market
- 26.1. Overview
- 26.2. Market Revenue, by Offering (2017-2030)
- 26.3. Market Revenue, by Application (2017-2030)
- 26.4. Market Revenue, by Test Type (2017-2030)
- 26.5. Market Revenue, by End User (2017-2030)
Chapter 27. Saudi Arabia Market
- 27.1. Overview
- 27.2. Market Revenue, by Offering (2017-2030)
- 27.3. Market Revenue, by Application (2017-2030)
- 27.4. Market Revenue, by Test Type (2017-2030)
- 27.5. Market Revenue, by End User (2017-2030)
Chapter 28. South Africa Market
- 28.1. Overview
- 28.2. Market Revenue, by Offering (2017-2030)
- 28.3. Market Revenue, by Application (2017-2030)
- 28.4. Market Revenue, by Test Type (2017-2030)
- 28.5. Market Revenue, by End User (2017-2030)
Chapter 29. U.A.E. Market
- 29.1. Overview
- 29.2. Market Revenue, by Offering (2017-2030)
- 29.3. Market Revenue, by Application (2017-2030)
- 29.4. Market Revenue, by Test Type (2017-2030)
- 29.5. Market Revenue, by End User (2017-2030)
Chapter 30. Competitive Landscape
- 30.1. List of Market Players and their Offerings
- 30.2. Competitive Benchmarking of Key Players
- 30.3. Product Benchmarking of Key Players
- 30.4. Recent Strategic Developments
Chapter 31. Company Profiles
- 31.1. Charles River Laboratories International Inc.
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.1.3. Key financial summary
- 31.2. Lonza Group Ltd.
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
- 31.2.3. Key financial summary
- 31.3. Merck KGaA
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
- 31.3.3. Key financial summary
- 31.4. InvivoGen
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
- 31.5. F. Hoffmann La Roche Ltd.
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
- 31.5.3. Key financial summary
- 31.6. Agilent Technologies Inc.
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
- 31.6.3. Key financial summary
- 31.7. Societe Generale de Surveillance SA
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.7.3. Key financial summary
- 31.8. WuXi AppTec
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.8.3. Key financial summary
- 31.9. BioMerieux S.A.
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.9.3. Key financial summary
- 31.10. Microcoat Biotechnologie GmbH
- 31.10.1. Business overview
- 31.10.2. Product and service offerings
- 31.11. Eurofins Scientific SE
- 31.11.1. Business overview
- 31.11.2. Product and service offerings
- 31.11.3. Key financial summary
- 31.12. Promega Corporation
- 31.12.1. Business overview
- 31.12.2. Product and service offerings
- 31.13. Thermo Fisher Scientific Inc.
- 31.13.1. Business overview
- 31.13.2. Product and service offerings
- 31.13.3. Key financial summary
- 31.14. Avance Biosciences Inc.
- 31.14.1. Business overview
- 31.14.2. Product and service offerings
- 31.15. Pacific BioLabs
- 31.15.1. Business overview
- 31.15.2. Product and service offerings
Chapter 32. Appendix
- 32.1. Abbreviations
- 32.2. Sources and References
- 32.3. Related Reports
